Literature DB >> 9134644

Modulation of blood cell activation by four commonly used anticoagulants.

C S Engstad1, T J Gutteberg, B Osterud.   

Abstract

In the past years, our group has made several observations suggesting that blood cells behave differently and when stimulated, release different levels of cytokines, depending on which anticoagulant the blood has been drawn into. The aim of this study was therefore to compare the effect of the four anticoagulants EDTA, citrate, heparin and hirudin on monocyte, neutrophil (PMN), and platelet function in human whole blood. Human whole blood was employed as an ex vivo model of cytokine production and protein secretion, and lipopolysaccharide (LPS) induced tissue factor (TF) activity in monocytes and LPS induced tumor necrosis factor alpha (TNF alpha) release were chosen as parameters of monocyte activation. Platelet factor 4 (PF4) secretion and LPS induced lactoferrin release were chosen as parameters of platelet and PMN activation, respectively. When human whole blood was stimulated with 5 ng/ml LPS for 2 h, TF activity in monocytes isolated from EDTA blood was found to be 2.9 mU/10(6) cells, whereas TF activity in monocytes isolated from citrated, heparinized and hirudinized blood was 14.7, 24.7 and 28.5 mU/10(6) cells, respectively. TNF alpha concentrations in platelet poor plasma (PPP) isolated from whole blood stimulated with 5 ng/ml LPS for 2 h was increased with 200, 400 and 350% in citrated, heparinized and hirudinized blood respectively, as compared to EDTA blood. Next, the effect of the anticoagulant on PMN secretion was measured. PPP isolated from whole blood incubated with 5 ng/ml LPS for 90 min contained 1170 ng/ml (EDTA blood), 2880 ng/ml (citrated blood), 4220 ng/ml (heparinized blood), and 5520 ng/ml lactoferrin (hirudinized blood). When studying the platelet parameter PF4, whole blood was incubated without any stimuli for 60 min, and we found that heparin PPP contained 1180 ng/ml PF4, while hirudin PPP contained 469 ng/ml, citrate PPP 440 ng/ml, and EDTA PPP 217 ng/ml PF4, respectively. Finally, the low molecular weight heparin compound Fragmin had no enhancing effect on PF4 levels in whole blood. It is concluded that the anticoagulant used in in vitro experiments has a large influence on the parameters measured.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9134644

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  15 in total

1.  Influence of low molecular weight heparin (certoparin) and unfractionated heparin on the release of cytokines from human leukocytes.

Authors:  M Köller; F Kutscha-Lissberg; J Brom; G Weidinger; G Muhr
Journal:  Inflammation       Date:  2001-10       Impact factor: 4.092

2.  Heparin and enoxaparin enhance endotoxin-induced tumor necrosis factor-alpha production in human monocytes.

Authors:  M Heinzelmann; M Miller; A Platz; L E Gordon; D O Herzig; H C Polk
Journal:  Ann Surg       Date:  1999-04       Impact factor: 12.969

3.  Enhanced incorporation of n-3 fatty acids from fish compared with fish oils.

Authors:  Edel O Elvevoll; Harald Barstad; Einar S Breimo; Jan Brox; Karl-Erik Eilertsen; Trine Lund; Jan Ole Olsen; Bjarne Osterud
Journal:  Lipids       Date:  2006-12       Impact factor: 1.880

4.  Protection of nonself surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicine.

Authors:  You-Qiang Wu; Hongchang Qu; Georgia Sfyroera; Apostolia Tzekou; Brian K Kay; Bo Nilsson; Kristina Nilsson Ekdahl; Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2011-02-21       Impact factor: 5.422

5.  Citrate modulates lipopolysaccharide-induced monocyte inflammatory responses.

Authors:  M J Ashbrook; K L McDonough; J J Pituch; P L Christopherson; T T Cornell; D T Selewski; T P Shanley; N B Blatt
Journal:  Clin Exp Immunol       Date:  2015-04-19       Impact factor: 4.330

6.  Multifunctional silk-heparin biomaterials for vascular tissue engineering applications.

Authors:  F Philipp Seib; Manuela Herklotz; Kelly A Burke; Manfred F Maitz; Carsten Werner; David L Kaplan
Journal:  Biomaterials       Date:  2013-10-04       Impact factor: 12.479

7.  Impact of Ultra-Sensitive technology and contemporary therapy on laboratory results.

Authors:  S Narayanan
Journal:  Indian J Clin Biochem       Date:  2001-01

8.  Establishment, Validation, and Initial Application of a Sensitive LC-MS/MS Assay for Quantification of the Naturally Occurring Isomers Itaconate, Mesaconate, and Citraconate.

Authors:  Moritz Winterhoff; Fangfang Chen; Nishika Sahini; Thomas Ebensen; Maike Kuhn; Volkhard Kaever; Heike Bähre; Frank Pessler
Journal:  Metabolites       Date:  2021-04-26

9.  Endogenous circadian regulation of pro-inflammatory cytokines and chemokines in the presence of bacterial lipopolysaccharide in humans.

Authors:  Shadab A Rahman; Oscar Castanon-Cervantes; Frank A J L Scheer; Steven A Shea; Charles A Czeisler; Alec J Davidson; Steven W Lockley
Journal:  Brain Behav Immun       Date:  2014-11-13       Impact factor: 7.217

10.  Constitutive STAT3 Phosphorylation in Circulating CD4+ T Lymphocytes Associates with Disease Activity and Treatment Response in Recent-Onset Rheumatoid Arthritis.

Authors:  Krista Kuuliala; Antti Kuuliala; Riitta Koivuniemi; Suvi Oksanen; Mari Hämäläinen; Eeva Moilanen; Hannu Kautiainen; Marjatta Leirisalo-Repo; Heikki Repo
Journal:  PLoS One       Date:  2015-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.